I now have comprehensive data from multiple authoritative sources. Here is the full, well-organized response:
Normal LH/FSH + Normal Total Testosterone + Low Free Testosterone
This pattern is a recognized and clinically important form of functional androgen deficiency. The core mechanism is elevated SHBG (Sex Hormone-Binding Globulin), which binds testosterone so tightly that total testosterone appears normal while the biologically active (free) fraction is reduced. Because the HPG axis "sees" total testosterone as normal, LH and FSH remain unsuppressed - hence the paradox of a eugonadotropic state with symptomatic androgen deficiency.
Pathophysiology
Circulating testosterone is distributed as:
- 2-4% free (unbound, immediately bioavailable)
- 44-65% SHBG-bound (tightly bound, biologically inactive)
- 33-50% albumin-bound (weakly bound; dissociates readily - considered "bioavailable")
SHBG binds testosterone with very high affinity (Ka = 10⁸-10⁹). When SHBG is elevated, a larger fraction of total testosterone is sequestered, reducing free and bioavailable testosterone despite a normal serum total. The pituitary responds to total (not free) testosterone through its feedback loop, so LH and FSH are not driven upward. The result: normal LH/FSH, normal total T, low free T.
(Tietz Textbook of Laboratory Medicine, 7th Ed.; Campbell Walsh Wein Urology)
Causes of Elevated SHBG Leading to This Pattern
| Category | Specific Causes |
|---|
| Physiologic | Advanced age (SHBG rises ~1-2%/year after age 40) |
| Endocrine | Hyperthyroidism, hypogonadism itself |
| Hepatic | Cirrhosis, chronic liver disease (SHBG synthesized in liver) |
| Medications | Anticonvulsants (phenytoin, valproate), estrogens, oral contraceptives |
| Genetic | SHBG gene polymorphisms - heritable variation in SHBG levels |
| Systemic | HIV infection, chronic systemic illness |
Note: Obesity, T2DM, hypothyroidism, nephrotic syndrome, and glucocorticoids lower SHBG (opposite scenario).
(Harrison's Principles of Internal Medicine 22E; Campbell Walsh Urology; Smith & Tanagho's General Urology)
How to Proceed: Diagnostic Workup
Step 1 - Confirm low free testosterone
- Measure free testosterone by equilibrium dialysis (gold standard) - direct immunoassay methods are unreliable.
- Alternatively, calculate free testosterone from total testosterone + SHBG + albumin using the Vermeulen equation.
- Free testosterone <225 pmol/L is associated with hypogonadism per EAU 2024 guidance.
Step 2 - Measure SHBG
- Will typically be elevated, explaining the discordance between total and free testosterone.
Step 3 - Look for the underlying cause of high SHBG
- Thyroid function tests (TSH, T3/T4) - rule out hyperthyroidism
- Liver function tests + hepatitis screen
- Review medications (anticonvulsants, exogenous estrogens)
- Consider age-related late-onset hypogonadism (LOH) if >40 years old
Step 4 - Contextualize symptoms
- Endocrine Society guidelines recommend diagnosing testosterone deficiency only when biochemical findings are accompanied by symptoms. If the patient is symptomatic + low free T, treatment is warranted even if total T is normal.
(Endocrine Society Guidelines 2018; AUA Guidelines 2018/2024; VA Clinical Recommendations Jan 2026)
Symptoms of Low Free Testosterone (androgen deficiency)
Sexual/Reproductive
- Decreased libido (most specific symptom)
- Erectile dysfunction / reduced erectile quality
- Oligospermia or azoospermia
- Testicular atrophy (variable)
Metabolic/Musculoskeletal
- Decreased muscle mass and strength
- Increased fat mass (especially central/visceral)
- Decreased bone mineral density → risk of osteopenia/osteoporosis
- Reduced exercise tolerance
Neuropsychiatric
- Fatigue and low energy
- Depressed mood, irritability
- Poor concentration and cognitive performance
- Reduced motivation and "enjoyment of life"
Other
- Anemia (normocytic)
- Sleep disturbances
- Hot flashes (less common in men than women)
- Gynecomastia (especially if estrogen:androgen ratio is elevated)
The landmark EMAS (European Male Aging Study) showed that low free testosterone specifically correlated with hypogonadal signs/symptoms even in men with normal total testosterone - confirming this pattern as a genuine clinical syndrome (cited in Smith & Tanagho's General Urology as: Antonio L et al, J Clin Endocrinol Metab 2016;101:2647).
Treatment Modalities
1. Treat the Underlying Cause (First Priority)
- Correct hyperthyroidism - normalizing thyroid function can reduce SHBG and restore free testosterone
- Manage liver disease
- Substitute/discontinue SHBG-elevating medications if possible
- Weight loss (if applicable) - while obesity lowers SHBG, achieving ideal weight generally improves the androgen milieu
2. Lifestyle Modification
- Weight reduction and resistance exercise
- Adequate sleep (testosterone and SHBG have diurnal variation)
- Alcohol limitation (alcohol promotes SHBG)
- Stress reduction
3. Testosterone Replacement Therapy (TRT)
Indicated when symptoms persist despite optimizing reversible causes, and free testosterone remains low.
Target: Physiologic testosterone levels of 400-800 ng/dL.
| Route | Preparation | Dosing | Notes |
|---|
| Transdermal gel | AndroGel 1-2%, Testim, Axiron | 50-100 mg/day to skin; delivers 5-10 mg systemically | Most used in US; avoid skin-to-skin transfer to women/children |
| Transdermal patch | Androderm | 2-4 mg/day (nonscrotal) | Consistent levels; 30-40% skin irritation rate |
| Intranasal gel | Natesto | 5.5 mg per nostril, 3x/day | No transfer risk; short-acting |
| IM injection | Testosterone enanthate or cypionate | 150-200 mg every 2-3 weeks IM; or 50-100 mg weekly SC | Weekly SC gives more stable levels; peak-trough variation |
| Long-acting IM | Testosterone undecanoate | 750 mg q10 weeks (after initial loading doses) | Preferred in Europe/Australia; 30 min observation needed |
| Buccal | Striant (mucoadhesive tablet) | 30 mg twice daily | Avoids first-pass hepatic metabolism |
| Subcutaneous pellets | Testopel (75 mg/pellet) | 4-6 pellets q4-6 months | Convenient; minor surgical procedure |
| Oral | Testosterone undecanoate capsules | 158-396 mg twice daily with food | Self-emulsifying formulation; newer option |
Avoid: 17α-alkylated androgens (methyltestosterone) - hepatotoxic, dyslipidemic.
(Goldman-Cecil Medicine; Harrison's 22E; Katzung's Pharmacology 16th Ed)
4. SERMs (Selective Estrogen Receptor Modulators)
- Clomiphene citrate (off-label) - blocks estrogen negative feedback at the hypothalamus, increases LH/FSH and endogenous testosterone production.
- Useful in men who wish to preserve fertility, as TRT suppresses spermatogenesis.
- Not licensed for testosterone deficiency in most countries.
5. Aromatase Inhibitors
- Anastrozole, letrozole (off-label) - reduce peripheral conversion of testosterone to estradiol.
- Can modestly raise free testosterone by reducing estrogen-mediated SHBG upregulation.
- Limited evidence; not first-line.
Monitoring on TRT
- Serum testosterone (free + total): 3-6 months after initiation, then annually. Target mid-normal range.
- PSA + digital rectal examination: before starting, at 3-6 months, then annually.
- Hematocrit/hemoglobin: elevated erythropoiesis is the most common dose-dependent side effect. Hold if hematocrit >54%.
- Bone mineral density: DEXA at baseline if osteopenia suspected; recheck in 1-2 years.
- Liver function (if using oral agents).
- Lipid panel and cardiovascular risk assessment.
Contraindications to TRT
- Known or suspected prostate cancer
- Breast cancer in men
- Polycythemia (Hct >54%)
- Untreated obstructive sleep apnea
- Severe lower urinary tract symptoms (IPSS >19)
- Desire for fertility in the near term
- Recent MI or stroke (<6 months)
- Uncontrolled heart failure
- Thrombophilia
(Endocrine Society Clinical Practice Guideline 2018; Campbell Walsh Urology)
Summary Algorithm
Normal LH/FSH + Normal Total T + Low Free T
↓
Measure SHBG → likely ELEVATED
↓
Identify cause: age / hyperthyroidism / liver disease / medications
↓
Assess symptoms (libido, energy, mood, muscle mass, ED, bone density)
↓
Symptomatic?
├─ YES → Treat underlying cause + lifestyle modification first
│ → If insufficient: TRT (gel/patch/injection based on preference)
└─ NO → Monitor annually; no pharmacologic treatment needed
Recent evidence note: A 2024 review (PMID 39445719, Curr Opin Endocrinol Diabetes Obes) highlights that calculated free testosterone has both advantages and limitations and should be interpreted alongside clinical context, not used as the sole treatment trigger.